That could potentially be the confirmatory trial needed to back up SRP-9001's accelerated approval, if granted. Sarepta's current exon-skipping DMD therapies – Exondys 51 (eteplirsen), Vyondys ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback